Collaborations & Alliances

Regenxbio, Neurimmune to Develop Antibodies for Neurodegenerative Disease Treatment

Potential to deliver sustained levels of therapeutic human antibodies to the brain with AAV vectors

Regenexbio and Neurimmune AG have entered an exclusive license, development and commercialization agreement to discover and develop novel AAV gene therapies using NAV Vectors to deliver human antibodies against targets implicated in chronic neurodegenerative diseases, including tauopathies.   “Regenexbio is at the forefront of research and development of AAV-mediated antibody gene therapies,” said Olivier Danos, chief scientific officer, Regenexbio. “We are thrilled to initiate...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters